All In Biotech

Drug Trial Radar · NCT01764633

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease

Last checked: Nov 20, 2026Latest source record: May 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 27,564 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

27,564

Actual

Start

Feb 8, 2013

Primary completion

Nov 11, 2016

Study completion Nov 11, 2016

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Jan 9, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 40 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective was to evaluate the effect of treatment with evolocumab, compared with placebo, on the risk for cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization, whichever occurs first, in patients with clinically evident cardiovascular disease.

Conditions

  • Dyslipidemia

Interventions

  • EvolocumabBiological

    Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.

  • PlaceboDrug

    Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary RevascularizationTime frame: Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.

Locations

1,284 sites in 49 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Birmingham, Alabama

  • Research Site

    Huntsville, Alabama

  • Research Site

    Mobile, Alabama

  • Research Site

    Anchorage, Alaska

  • Research Site

    Glendale, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Tucson, Arizona

  • Research Site

    Alhambra, California

  • Research Site

    Banning, California

  • Research Site

    Beverly Hills, California

  • Research Site

    Encino, California

  • Research Site

    Escondido, California

  • Research Site

    Glendale, California

  • Research Site

    Harbor City, California

  • Research Site

    Huntington Beach, California

  • Research Site

    Laguna Hills, California

  • Research Site

    Long Beach, California

  • Research Site

    Long Beach, California

  • Research Site

    Los Alamitos, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Newport Beach, California

  • Research Site

    Oceanside, California

  • Research Site

    Oxnard, California

  • Research Site

    Palm Springs, California

  • Research Site

    Roseville, California

  • Research Site

    Sacramento, California

  • Research Site

    San Diego, California

  • Research Site

    San Diego, California

  • Research Site

    San Pedro, California

  • Research Site

    Santa Ana, California

  • Research Site

    Tarzana, California

  • Research Site

    Thousand Oaks, California

  • Research Site

    Torrance, California

  • Research Site

    Torrance, California

  • Research Site

    Valley Village, California

Showing 40 of 1,284 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.